Seth Lederman, Tonix Pharmaceuticals CEO

Small, strug­gling biotech winds up with a 3X los­er as an­oth­er PhI­II of its lead drug col­laps­es

Lit­tle Tonix Phar­ma­ceu­ti­cals has run in­to an­oth­er brick wall as its lead drug — a re­for­mu­lat­ed mus­cle re­lax­ant orig­i­nal­ly ap­proved 44 years ago — has failed an­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.